Latest Listings And Ipos News

High-Tech Metals reports strong drilling results at Wagtail Gold Deposit and secures $10.7 million from option exercises, advancing its Mt Fisher and Mt Eureka gold projects.

Next Science Limited has updated the payment date for its cash return of capital to 10 February 2026, following its recent asset sale and pending ASX delisting.

Austral Gold Limited has restarted commercial production at its Casposo mine, driving a 170% surge in quarterly sales revenue to US$23.8 million and strengthening its financial position with reduced debt and increased cash reserves.

Golden Cross Resources reported a quiet December quarter with ongoing preparatory work at its flagship Copper Hill copper-gold project, while its ASX securities remain suspended pending operational compliance.

Triton Minerals has executed a key agreement advancing the sale of 70% of its Mozambique graphite assets and completed initial drilling at its Aucu gold-copper project, positioning the company for growth amid stable operating conditions.

American Tungsten & Antimony Ltd (ASX, AT4) has initiated drilling at its Utah antimony project and expanded its Nevada tungsten portfolio, while preparing a spin-out IPO of Australian assets to sharpen its US focus.

ADX Energy reported a 24% drop in production due to mechanical issues but is advancing well workovers and new drilling, supported by a $3.5 million capital raise and plans for a dual listing in Oslo.

Hydrix Limited reported $2.3 million in revenue for Q2 FY26 and secured a $2.5 million initial contract with SynCardia Systems to develop a fully implantable artificial heart, setting a positive tone for 2026.

Audio Pixels Holdings Limited reported a $7.2 million loss for the half-year ending June 2025, while making significant strides in refining its MEMS digital loudspeaker fabrication process and securing a $6 million loan facility.

GCM Corporation’s latest quarterly report confirms its VHD thermal management technology outperforms copper and aluminium, while commercial and US listing plans gain momentum.

4DMedical Limited has responded to ASX queries over its announcements of commercial agreements with leading US academic medical centres, clarifying its disclosure approach and denying ramping allegations ahead of a $150 million capital raise.

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.